A CONTRACT OF A

**Original Research Paper** 

**Gynae**cology

# **VULVAL CARCINOMA A RARE ENTITY: A CASE REPORT**

Asha Nirmala Sabbella*	Post Graduate, KIMS&RF, Amalapuram. *Corresponding Author
Peddi Swathi Goud	Post Graduate, KIMS&RF, Amalapuram.
Maganti Rekha	Post Graduate, KIMS& RF, Amalapuram.

ABSTRACT Vulval malignancy is a rare entity and it occur in 2 different types – HPV induced type in younger women, may develop from VIN and non HPV dependent type in older post menopausal women as a result of chronic inflammation [itch – scratch – lichen sclerosis hypothesis]. A 52 year old postmenopausal lady came to OPD with C/O growth on vulvar region since 10 yrs, insidious onset, associated with itching, later it got ulcerated and she developed burning sensation.on further examination diagnosed as early vulval cancer[T1b] and underwent radical local excision with 1 cm grossly negative margine. Currently, a more individualized and less radical treatment is suggested. The gold standard treatment for even a small invasive carcinoma of vulva was historically radical vulvectomy with removal of the tumor with a wide margin flb an enbloc resection of the inguinal and often pelvic lymph nodes

# **KEYWORDS**: Age, vulval, pap smear, FNAC, CECT abdomen and pelvis, Biopsy.

# INTRODUCTION:

Vulvar malignancy is a rare entity and it occur in 2 different types – HPV induced type in younger women, may develop from VIN and non HPV dependent type in older post menopausal women as a result of chronic inflammation [itch – scratch – lichen sclerosis hypothesis]. Diagnosis based on histology and treatment is surgical resection. There has been a recent trend toward more conservative surgery to decrease psychosexual complications.

### Case Report:

A 52 year old postmenopausal lady came to OPD with C/O growth on vulvar region since 10 yrs , insidious onset, associated with itching ,later it got ulcerated and she developed burning sensation.pt was k/c/o type 2 DM on insulin since 9yrs.

#### **Examination:**

P/A-Soft , no palpable masses.Both labia majora hypertrophied and pigmented with proliferative growth of  $4\times4$  cm with ulceration present on the lower  $1/3^{rd}$  of left labia majora and another proliferative growth of  $3\times4$  cm with ulceration on the lower  $1/3^{rd}$  of right labia majora [extending on to the perineal skin] present. P/V vagina not indurated, Ut NS/M/AV/FF /NO FT . P/R Rectal mucosa free, O/E no palpable lymphnodes.(figure:1)



### Figure: 1

# Investigations:

Biopsy – well differentiated squamous cell carcinoma. FNAC –Inguinal lymph nodes – Negative for malignancy.CECT ABDOMEN & PELVIS – NO obvious infiltration of urethra; Vagina and anal canal. PAP SMEAR–NILM Diagnosis: Early Vulval cancer [T1b]



#### Figure:2

## HPE REPORT :

Well differentiated squamous cell carcinoma [all margins are free from growth]

## DISCUSSION:

Vulvar cancer accounts for 5% of all malignancies of female genital tract. Pruritus is the most common non specific symptom. The gold standard treatment for even a small invasive carcinoma of vulva was historically radical vulvectomy with removal of the tumor with a wide margin flb an enbloc resection of the inguinal and often pelvic lymph nodes.Radical vulvectomy can be performed by butterfly incision as well as triple incision . The butterfly incision technique involves en-bloc removal of lymphnodes along with vulvectomy, through a single incision. This technique causes increased perioperative blood loss, operative time and severe post op morbidity. This morbidity can be reduced by the triple incision technique.It is performed by 3 separate incisions , 2 for bilateral groin lymphnodes and a separate incision for vulvectomy.In larger primary tumors vulvectomy with B/L inguinofemoral LN dissection is indicated.

### CONCLUSION:

Currently, a more individualized and less radical treatment is

suggested; a radical wide local excision is possible in the case of localized lesions[T1]. A Sentinel LN biopsy may be performed to reduce wound complications and lymphedema. (figure:3)



# Figure:3

#### **REFERENCES:**

- 1.
- NOVAK'S GYNECOLOGY 16<sup>TH</sup> EDITION. SHAW'S GYNECOLOGY 17<sup>TH</sup> EDITION,Hoffman MS 3LapollaRobert WS ,Cancer Research U.K, Homesley HD,Bundy BM ,ROYAL COLLEGE OF PATHOLOGISTS, ANDERSON BL, Hacker NF,Berek js,Zhang sh sood AK. 2.